Introduction
The therapeutic delivery of potentially neuroprotective or restorative molecules, such as growth factors to the central nervous system (CNS), requires highly specific intraparenchymal targeting to overcome obstacles of delivery imposed by the blood-brain barrier, to achieve high local concentrations of the substance of interest, and to prevent adverse affects from spread of the therapeutic substance to non-targeted brain regions. Gene therapy is a potentially effective means of achieving these goals. [1] [2] [3] [4] [5] [6] [7] [8] However, the availability of a safe and effective means of controlling transgene expression is a highly desirable feature that would potentially facilitate the translation of gene therapy approaches from promising findings in animal models to humans with Alzheimer's disease, 3, 9 Parkinson's disease, 2 and motor neuron disease. 5, 10 Such regulatable expression would permit the doses of gene product to be reduced and, if necessary, discontinued in the event that adverse events occurred in the clinical setting.
Several different systems have been developed as potential tools for controlled gene expression, including tetracycline-based regulatory systems. 11, 12 Previously, we and others have shown that the tetracycline-based system can be incorporated into single retroviral vectors to control expression of foreign genes in vitro. [13] [14] [15] [16] However, control of biological events such as neuronal rescue and axon growth in vivo in response to regulated CNS gene neurons, NGF-mediated neuronal rescue and axonal growth could be completely controlled over a 2-week period by the addition or removal of the tetracycline modulator doxycycline in the animals' drinking water. Further, continued expression of the reporter gene GFP could be reliably and repeatedly turned on and off in the injured CNS for at least 3 months post-grafting, the longest time point investigated. These data constitute the first report of regulated neuronal rescue and axonal growth by controlled neurotrophin gene delivery and long-term, regulated expression using ex vivo CNS gene therapy. Gene Therapy (2001) 8, 954-960.
therapy have not been reported to date. In the present study, we investigated the potential of the tetracycline regulatable system (tet-off-system) to regulate expression of the nervous system growth factor nerve growth factor (NGF), or the control gene green fluorescent protein (GFP), in primary rat fibroblasts grafted to the CNS. Previously in unregulated vector systems, we reported that ex vivo NGF gene delivery prevents the death and reverses the age-related atrophy of adult basal forebrain cholinergic neurons in rodents and primates. 1, 3, 9, 17 In the present study, we examined whether NGF gene delivery using the tetracycline regulatable system would lead to accurate control of cell death and axon growth in the in vivo cholinergic model system in rodents, a correlational model of Alzheimer's disease. In addition, we examined whether long-term control of gene expression in vivo was sustainable in the injured CNS environment. We now report for the first time the in vivo control of neuronal survival and axon growth using regulatable vector systems.
Results
Retroviral vectors for the controlled expression of NGF and GFP were based on the tetracycline regulatable system and were constructed as previously described (Figure 1) . 12, 13, 16 Previously we demonstrated in vitro that primary fibroblasts transfected with these vectors exhibited between 36-and 52-fold regulation of NGF expression in vitro. 16 To investigate if regulated delivery of neurotrophic factors has effects on neuronal rescue and axonal growth in vivo, we utilized a well-established model of basal forebrain neuron degeneration, the fim- Doxycycline administration controls neuronal rescue Adult Fischer 344 rats underwent unilateral fimbria-fornix lesions and received either control GFP expressing cells (n = 5) or cells genetically modified with a vector for the regulatable expression of NGF (tet-off-NGF; n = 10). Half of the animals in the NGF group received doxycycline in the drinking water to turn gene expression off. After 2 weeks, the number of remaining neurons immunolabeled for the cholinergic marker choline acetyltransferase (ChAT) was reduced to 37 ± 6% on the lesioned side of the brain in animals that received control grafts expressing GFP; this amount of cholinergic loss is consistent with previous reports 17, 22, 23 (Figure 2A, D) . In contrast, animals that received grafts of NGF-secreting cells without doxycycline treatment (ie NGF continued to be expressed by cells) exhibited substantial neuronal protection, with persistence of neuronal labeling for ChAT in 75 ± 13% of cholinergic neurons ( Figure 2B , E, Figure 3 ). The magnitude of this rescue was within the range of previous reports using constitutive, unregulated NGF delivery by primary fibroblast grafts. 23 However, administration of doxycycline in the drinking water (thereby turning off NGF expression) resulted in a marked loss of cholinergic neuronal labeling after fimbria-fornix lesions, with a persistence of only 42 ± 4% of labeled neurons ( Figure 2C , F). Overall group differences were significant (ANOVA, P Ͻ 0.05; doxycycline-treated animals did not differ from GFP-grafted animals on posthoc Fischer's testing). Thus, gene expression could be repressed in vivo, thereby eliminating detectable effects on neuronal survival. Doxycycline administration controls axonal growth Doxycycline administration was also able to control axon growth. In control-grafted subjects that underwent fimbria-fornix transections, little penetration of GFPexpressing cell grafts was evident on choline-acetyl-transGene Therapy ferase (ChAT) labeling ( Figure 4A ). In contrast, grafts in animals that received NGF-secreting cells without doxycycline therapy (ie NGF turned on) were densely penetrated by cholinergic axons ( Figure 4B ). However, when doxycycline was administered to animals with NGFsecreting grafts, axonal penetration of grafts was nearly eliminated ( Figure 4C ). Overall group differences were present by ANOVA (overall, P Ͻ 0.01), and the GFPtreated and doxycycline-treated, NGF-grafted groups did not differ from one another on post-hoc testing ( Figure  4D ; P = 0.86). Thus, once again, gene expression could be repressed in vivo, eliminating detectable axonal growth in response to NGF.
Doxycycline administration continues to control gene expression for extended time periods of at least 3 months in vivo To determine whether doxycycline administration would continue to regulate transgene expression for prolonged time periods under harsher in vivo conditions, GFPexpressing cells were grafted to the lesioned spinal cord. For this set of experiments, a model of spinal cord injury was chosen because unlike the fimbria-fornix lesion model, in which there is minimal disruption of the cellular environment in the region of grafts, a region of spinal cord injury is characterized by extensive parenchymal disruption. The injured environment sustains inflammation, free radical formation, chemokine and cytokine activation, and cellular degeneration. Thus, this milieu might challenge the ability of regulatable systems to modulate gene expression. Adult Fischer 344 rats (n = 19) underwent spinal cord transection lesions that disrupted from one-half to all of the spinal cord at the T7 level, as previously reported. [24] [25] [26] Fibroblasts were transfected with the tetracycline regulatable vector expressing the GFP reporter gene. Cells were embedded in a collagen gel to prevent their diffusion away from the lesion cavity, and were placed directly in the spinal cord injury site ( Figure 5 ).
In one set of animals, persistence of expression of the GFP gene was assessed immunocytochemically at 2 weeks (n = 3), 6 weeks (n = 3) or 3 months (n = 2) after grafting in the absence of doxycycline (hence with gene expression on). Gene expression was readily detectable at all three time points, with no evident loss of GFP expression by immunolabeling throughout this period ( Figure 5 ). Thus, silencing of the regulatable CMV promoter was not evident up to 3 months after grafting.
In a second set of animals that also survived for either 2 weeks (n = 3), 6 weeks (n = 3) or 3 months (n = 2) post-grafting to spinal cord lesion sites, doxycycline was continuously administered to suppress gene expression. Gene expression was absent in virtually all cases; only rarely, very faintly labeled GFP cells were present at the 3 month time points ( Figure 5 ). Thus, gene expression was readily suppressable throughout the experimental period.
In a third set of animals, the ability to suppress gene expression after it had been induced in vivo was tested. Animals (n = 3) that received grafts of GFP-expressing cells to the lesion site were not treated with doxycycline for the first 6 weeks after grafting (hence, gene expression was on). For the subsequent 6 weeks in vivo, doxycycline was then administered to suppress gene expression. On histological examination, GFP immunolabeling was vir- tually absent in all sections ( Figure 5 ). Thus, following induction of gene expression in vivo, expression can subsequently be turned off.
Discussion
The present experiments demonstrate for the first time that neuronal survival, axon growth and gene expression can be successfully regulated in the adult CNS using a tetracycline-regulatable ex vivo gene delivery system. Primary fibroblasts grafted to different CNS locations and cellular milieus can be regulated for extended time periods in vivo. Regulated expression of the neurotrophic factor NGF establishes significant control over neuronal survival and axonal growth in vivo using orally administered agents, providing a valuable biological tool for regulating host responses to genetically delivered substances. Gene expression was efficiently and reversibly controlled for at least 3 months after grafting.
The implications of controlled gene expression in the CNS are at least two-fold. First, the safety profile of ex vivo gene therapy is improved if the transgene can be turned on and off by oral administration of doxycycline. For certain applications, such as growth factor delivery in Alzheimer's disease, 3, 7, 9 Parkinson's disease 2 and motor neuron disease (amyotrophic lateral sclerosis), 5,10 the presence of regulatable expression systems would facilitate the translation of these approaches to clinical trials by providing a means of discontinuing gene therapy in the event that adverse effects occur. A clinical trial of ex vivo NGF gene therapy is currently underway in Alzheimer's disease, because adverse effects of long-term constitutive NGF delivery have not been observed in extensive primate studies (M Tuszynski and A Blesch, unpublished data). However, the availability of regulatable systems would add a heightened level of safety to such studies. Second, regulatable expression systems offer the potential to actually enhance the in vivo efficacy of growth factor delivery in models of nervous system disease by controlling axonal entry and egress from lesion sites. For example, in the injured spinal cord, axons readily penetrate grafts of growth-factor secreting cells placed in lesion sites. [25] [26] [27] [28] However, axons fail to exit such grafts in most cases. Regulatable systems could be used to promote axonal entry into grafts while neurotrophin gene expression is turned on; then, after axons have fully penetrated grafts in lesion sites, gene expression could be turned off, thereby hypothetically allowing axonal egress from grafts and into the denervated host spinal cord. The biological implications of this approach are now being examined in vivo.
Tetracycline-mediated regulation of reporter transgene expression in the CNS has previously been reported using adenoviral vectors. 29, 30 However, continued gene expression in the latter studies was achieved only after immunosuppressing animals to mitigate the toxicity and immunogenity of adenoviral antigens. 30 In the present experiment, immunosuppression was not necessary due to the autologous nature of the grafted cells. Further, although bacterial elements were present within the tetracycline transactivator, immune reactions were not detected on Nissl staining, and gene expression appeared to be tightly regulated.
The present experiments used the so-called 'tet-off' system, in which tetracycline binds to a repressor element which blocks gene transcription. 12 An inverted system for the tetracycline-mediated activation of transcription has also been described (the 'tet-on' system) and is currently used in retroviral vector expression systems. 11, 31 In fact, the 'tet-on' system may be desirable for shorter-term applications of gene therapy in the nervous system, wherein the availability of a drug that promotes gene expression would be used to transiently express the gene product for a defined period of time (eg to elicit axonal growth after a spinal cord injury). On the other hand, a negative regulatable ('tet-off') system might be more useful in potential applications to chronic nervous system disease, wherein one would predict a need for long-term Gene Therapy
Figure 4 Growth of cholinergic axons in response to regulated NGF expression (ChAT labeling). (A) Very few neurites are present in GFP grafts after fimbria-fornix lesions. (B) NGF-secreting grafts in animals that did not receive doxycycline (NGF is turned on) were densely penetrated by cholinergic axons, whereas (C) NGF-secreting grafts in animals that did receive doxycycline (NGF is turned off) exhibit very few axons. (D) Quantification of neurite density in tet-off-NGF-and GFP-grafted animals demonstrates highly significant differences when NGF expression is turned on or off by doxycycline (P Ͻ 0.01). Scale bar, 27.5 m; g, graft; h, host; host/graft interfaces are outlined by dashed lines.
in vivo gene delivery (in the absence of an orally delivered drug). In the latter instance, should it become necessary to discontinue gene expression while treating chronic disease, this could be accomplished by oral administration of a tetracycline analog.
In summary, tetracycline-mediated regulation of gene expression may allow for controlled nervous system growth factor delivery in neurodegenerative diseases and CNS trauma. The availability of practical regulatable expression systems could enhance the effectiveness and safety of CNS gene therapy. The present study provides a basis for future therapeutic applications of regulated ex vivo CNS gene therapy.
Materials and methods
Vector construction and cell culture The construction of retroviral vectors, establishment of primary fibroblasts and characterization of NGF secreting cells has been described previously. 16 Briefly, MLV-based retroviral vectors were used to transfect primary fibroblasts obtained from a skin biopsy. Vectors contained the human NGF or green fluorescent protein cDNAs that were under the control of a minimal CMV promoter coupled to tetracycline response elements. [12] [13] [14] [15] 29, 30 The tetracycline transactivator coding region was expressed by the 5Ј long terminal repeat.
Animal subjects
Adult female Fischer 344 rats weighting 160-200 g were housed under standard laboratory conditions with 12 h light dark cycle. The subjects had ad libitum access to food
Figure 5 Labeling for GFP reveals regulation of in vivo gene expression for at least 3 months in the injured spinal cord. (A, C, E) Animals grafted with tet-off-GFP that received no doxycycline (−Dox) in the drinking water continue to express the GFP transgene for 2 weeks (A), 6 weeks (C), and 3 months (E). (B, D, F) However, GFP expression is not detectable in animals treated continuously with doxycycline (+Dox) for (B) 2 weeks, (D) 6 weeks or (F) 3 months. (G) GFP expression is also undetectable in
animals that receive no doxycycline for the first 6 weeks after grafting (hence NGF expression is turned on), followed by treatment with doxycycline for the next 6 weeks to suppress GFP expression. Scale bar = 44 m; g, graft; h, host; g/h interface is outlined by arrows. and water; in some subjects (see below), doxycycline (1 mg/ml) was added to the drinking water.
Lesions and cell grafting
Fimbria-fornix lesions: Rats (n = 15) were deeply anesthetized (2 ml/kg) with a mixture of ketamine (25 mg/ml), rompun (1.3 mg/ml), and acepromazine (0.25 mg/ml). A small burr hole was drilled at coordinates AP + 0.3 mm; ML ± 0.5 mm. Next, animals received injections of either control GFP-expressing cells (n = 5) or cells containing tetracycline-regulatable NGF vectors (n = 10; DV −6.0 mm from the skull surface). 3 l of cells at a concentration of 10 5 cells/l were injected through a 25 gauge Hamilton syringe over 1 min. The needle was left in place for an additional 3 min, and was then withdrawn. Next, a 3 × 3 mm craniotomy was performed just caudal to bregma and immediately lateral to the sagittal sinus. Using a hand-held microaspiration device under visual guidance, the superficial parietal and cingulate cortices, supracallosal stria, and corpus callosum were removed, thereby exposing the fimbria-fornix. The latter was completely aspirated. 32, 33 The lesion cavity was filled with gelfoam and the skin layers were closed. Over the next 14 days, half of the NGF-grafted group received 1 mg/ml doxycycline and 5% sucrose in their drinking water, the other half received 5% sucrose only. Subjects were transcardially perfused 2 weeks later, the standard survival period for assessing neuronal survival in the fimbriafornix lesion model.
Spinal cord lesions: Animals (n = 19) were anesthetized as above, and T7 dorsal laminectomies were performed as previously described. 24 Briefly, the dura was opened and the spinal cord at T7 was transected over one-half to all of its ventral-dorsal dimension using a fine-tipped glass-pulled aspiration device. Eight subjects received GFP-expressing fibroblast grafts without doxycycline treatment and were killed after 2 weeks (n = 3), 6 weeks (n = 3) or 3 months (n = 2). Eight subjects received GFPexpressing fibroblasts with doxycycline treatment and were killed after 2 weeks (n = 3), 6 weeks (n = 3) or 3 months (n = 2). Three subjects received GFP-expressing fibroblasts without doxycycline treatment for 6 weeks, followed by addition of doxycycline to the drinking water for the next 6 weeks. In all cases, grafted fibroblasts were embedded in a matrix of liquid collagen (Sigma, St Louis, MO, USA) to prevent their leakage away from the lesion site. Post-operatively, animals received manual bladder evacuation for a period of approximately 10 days, and received IM-ampicillin (25 mg twice per day) to prevent urinary tract infections.
Tissue processing, immunolabeling and quantification Animals with fimbria-fornix transections were transcardially perfused with 100 ml cold 0.1 m phosphatebuffered saline (PBS) followed by 300 ml 2% paraformaldehyde/0.2% parabenzoquinone in phosphate buffer. Brains were removed and coronal sections were cut on a sliding microtome set at 40 m thickness. One out of 12 sections was mounted for Nissl staining, and adjacent series of sections were labeled with antibodies direct against choline acetyltransferase (goat-anti-ChAT at 1:500; Chemicon, Temecula, CA, USA) as previously described. 24 Total numbers of ChAT-labeled neurons in the medial septal nucleus were quantified through the rostral-to-caudal extent of the medial septum, as previously described. 17, 34 Briefly, cell bodies that were ChAT-labeled and possessed pyramidal neuronal morphology or clearly visible neuronal processes were quantified. Cells lying dorsal to a line drawn between the midpoint of the right and left branch of the anterior commissure were included in quantification, marking the border between the septal nucleus and the vertical limb of the diagonal band. Total cell numbers were expressed as the number of labeled cells on the lesioned (right) side of the brain divided by the number of cells on the intact (left) side of the brain in the same subject; thus, each animal served as its own control. Stereological quantification was not utilized because relative proportions of neurons on the lesioned versus intact side were examined, rather than absolute numbers of neurons. In addition, histological sections in GFP-grafted subjects were labeled with rabbit-anti-GFP antibody (1:6000; Molecular Probes, Eugene, OR, USA) to assess in vivo gene expression.
The density of axons penetrating grafts placed in the medial septum was measured using NIH Image software analysis of ChAT-labeled sections, as previously described. 24 Briefly, an image of each graft transmitted through a Sony high resolution camera was transmitted and captured in the NIH software program. The graft was outlined, and contrast between axons and the background was optimized by an operator blinded to the nature of the experimental manipulation. Identical settings of light level and contrast were utilized in measurements between subjects. The relative density of cholinergic axons in the graft was then measured as the number of pixels occupied by ChAT reaction product per the measured area. Axon density was measured in the entire graft at 200 × magnification; graft area and density were noted. Measurements were made in five GFP, four tet-off-NGF, and four tet-off-NGF-Dox-treated subjects.
Animals with grafts of GFP-expressing cells to the spinal cord were perfused with 4% paraformaldehyde, spinal cords were removed, post-fixed overnight and cryoprotected. Sagittal sections were cut on a cryostat set at 35 m intervals. Every seventh section was mounted on glass slides for Nissl staining. To assess in vivo gene expression, one out of seven sections was immunolabeled using the GFP antibody described above.
Statistical analysis
Groups were compared using analysis of variance followed by Fisher's post-hoc analysis. Values are presented as mean ± standard error of the mean.
